The antidepressant drug, sertraline, hinders bone healing and osseointegration in rats' tibiae

J Clin Periodontol. 2018 Dec;45(12):1485-1497. doi: 10.1111/jcpe.13015. Epub 2018 Nov 5.


Aim: Selective serotonin reuptake inhibitors (SSRIs) are one of the most common antidepressant drugs. SSRI use is associated with increased risk of bone fracture and titanium implant failure. The aim of this in vivo study was to investigate the effect of SSRIs on osseointegration and bone healing.

Materials and methods: On a total of 24 Sprague-Dawley rats, a custom-made titanium implant was placed in the left tibia, while a unicortical defect was created in the right tibia. Rats were assigned randomly into two groups and received a daily dose of either sertraline (5 mg/kg) or saline. After two weeks, they were euthanized and bone healing and osseointegration were assessed by micro-CT and histology.

Results: Bone formation in bone defects was significantly lower (p < 0.05) in sertraline-treated rats (BV/TV = 20.67 ± 11.98%) compared to the controls (BV/TV = 37.87 ± 9.56%). Furthermore, the percentage of osseointegration was significantly lower (p < 0.05) in sertraline-treated rats (34.40 ± 7.17%) compared to the controls (54.37 ± 8.58%).

Conclusion: Sertraline hinders bone healing and implant osseointegration.

Keywords: bone healing; cytokine; osseointegration; proteome; selective serotonin reuptake inhibitors; sertraline.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antidepressive Agents
  • Osseointegration*
  • Rats
  • Rats, Sprague-Dawley
  • Sertraline
  • Tibia*
  • Titanium


  • Antidepressive Agents
  • Titanium
  • Sertraline